Loading quotes...

Forecast

The analysts' average price target is €191.92 (+21.12%). The median is €191.92 (+21.12%).

Buy	6
Hold	4
Sell	0

News Go to news feed

Balchem beats Q1 expectations and records 27th consecutive quarter of EBITDA growth

Balchem reported adjusted EPS of $1.33 for Q1 2026 (consensus $1.25) and revenue of $270.7 million (consensus $265.8 million). Adjusted EBITDA rose 12.1% to $74.3 million with a margin of 27.4%, marking the company’s 27th consecutive quarter of EBITDA growth. Despite strong metrics, the stock fell about 2% premarket, partly due to profit-taking near the 52-week high. Management emphasizes robust cash flow, low net leverage (net debt/EBITDA 0.3x) and strategic growth initiatives, but sees risks from commodity inflation and currency fluctuations. » More on de.investing.com
Balchem beats Q1 expectations with stronger margin, stock slips in premarket

Balchem reported adjusted EPS of $1.33 for Q1 2026 (forecast $1.25) and revenue of $271 million (expectation $265.8 million), with both metrics topping analyst estimates. Gross margin rose 210 basis points to 37.3% and adjusted EBITDA grew 12.1%, marking the company’s 27th consecutive quarter of EBITDA growth. Despite the results, the stock fell about 2% premarket; management pointed to operational efficiency, pricing strategies and an optimistic outlook with expected further revenue gains. » More on de.investing.com
Balchem achieves over 1 billion USD in revenue for first time in 2025, quarterly profit beats expectations

Balchem reported adjusted EPS of $1.31 for Q4 2025 versus $1.18 expected, and revenue of $263.6 million, slightly above consensus. For fiscal 2025, consolidated revenue was $1,037.2 million (+8.8%), adjusted EBITDA was $274.9 million and adjusted net income was $167.9 million, with margins expanding to 26.5%. Net debt fell to 0.3x EBITDA, free cash flow increased significantly, and the annual dividend was raised by 10% to $0.96. Management remains cautiously optimistic for 2026, sees growth potential from international expansion, product innovation and targeted M&A, but cautions about input-cost and macroeconomic risks. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Balchem Co. has already paid €0.82 in dividends. The last payout was in January.

Financials

In the last quarter, Balchem Co. had revenue of €256.61m and net profit of €41.25m

(EUR)	September 2026	YoY
Revenue	256.61m	12.55%
Gross profit	93.33m	14.74%
Net profit	41.25m	20.16%
EBITDA	63.95m	13.79%

Fundamentals

Metric	Value
Market capitalization	€5.04bn
Number of shares	31.88m
52-week high/low	€164.16 - €131.38
Dividend yield	0.52%
Dividends TTM	€0.82
Beta	0.85
P/E ratio	33.15
PEG ratio	2.06
P/B ratio	4.27
P/S ratio	5.09

Company profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.

Name	Balchem Co.
CEO	Theodore L. Harris
Headquarters	Montvale, nj USA
Website	balchem.com
Sector	Consumer Staples
Industry	Food Products
IPO	03/06/1986
Employees	1,379